LEHI, Utah, Sept. 4, 2025 /PRNewswire/ -- Halia Therapeutics, Inc., a clinical-stage biopharmaceutical company developing first-in-class anti-inflammatory therapies, today announced…
MILAN, July 17, 2025 /PRNewswire/ -- A recently published five-year pharmacovigilance study confirms the excellent safety profile of a fixed-dose combination…